Introduction {#sec1}
============

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which was declared a global pandemic by the World Health Organization (WHO) on 11^th^ March 2020. SARS-CoV-2 was discovered in December 2019 in Wuhan City, Hubei Province, China. The origin of the virus is unknown, but initially, newly diagnosed cases were linked to the Huanan Seafood Wholesale Market where people can buy wild animals, such as bats \[[@bib1]\]. SARS-CoV-2, a novel enveloped RNA betacoronavirus, has phylogenetic similarity to severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus \[[@bib2]\].

One of the characteristics of COVID-19 is that it is highly contagious; China and 164 other countries have been affected in less than 3 months. Despite China reaching 81,151 confirmed cases with 3242 deaths, the country has reported only one new domestic case since 18^th^ March 2020. As of that date, the total worldwide confirmed cases was 193,475 with 7864 deaths (WHO). Although protective measures have been implemented in China (e.g. isolation from confirmed and suspected cases) to reduce spread of the virus, the need for effective treatment is imperative to stop the outbreak and reduce the morbidity and mortality of COVID-19 \[[@bib1]\].

Since the onset of the outbreak, many agents that could have efficacy against COVID-19 have been proposed. Various antiviral agents were included in the latest guidelines from the National Health Commission, including interferon, lopinavir/ritonavir, chloroquine phosphate, ribavirin and arbidol \[[@bib3]\]. Angiotensin receptor blockers, such as losartan, have also been suggested for the treatment of COVID-19 \[[@bib4]\].

The treatment guidelines for COVID-19 vary between countries. The WHO guidelines are very general, recommending management of symptoms, and advise caution with paediatric patients, pregnant women and patients with underlying co-morbidities. There is no approved treatment for COVID-19; the recommendation is to provide supportive management according to each patient\'s need (e.g. antipyretics for fever, oxygen therapy for respiratory distress). Moreover, WHO recommendations indicate that severe cases should be given empiric antimicrobial therapy, with mechanical ventilation implemented depending on the patient\'s clinical condition. Some of the Asian guidelines (e.g. the Japanese guidelines) were not easy to interpret as they have not yet been translated into English. However, the treatment protocols across countries are similar, and include hydroxychloroquine, chloroquine phosphate, remedesivir and lopinavir/ritonavir \[[@bib5], [@bib6], [@bib7]\]. Treatment guidelines between countries differ slightly, as shown in [Table I](#tbl1){ref-type="table"} \[[@bib8], [@bib9], [@bib10], [@bib11]\].Table IComparison between the treatment guidelines for coronavirus disease 2019 in Saudi Arabia, the USA, Europe and Egypt \[[@bib8], [@bib9], [@bib10], [@bib11]\]Table ISaudi Arabia (Ministry of Health)USA (Massachusetts General Hospital)Europe (Ireland)EgyptMild-to-moderateHydroxychloroquine\
Chloroquine\
Chloroquine phosphateClinical trial of remdesivirChloroquine (oral)\
Hydroxychloroquine (oral)\
Lopinavir/ritonavir (oral)\
Remdesivir (intravenous)Oseltamivir\
Hydroxychloroquine\
Chloroquine phosphateSevereHydroxychloroquine\
Chloroquine\
Chloroquine phosphate\
Combination therapy (lopinavir/ritonavir)Hydroxychloroquine\
Chloroquine\
Lopinavir/ritonavir\
Darunavir/cobicistatOseltamivir\
Hydroxychloroquine\
Chloroquine phosphate\
Lopinavir/ritonavir\
Serum ferritin, D-dimerCriticalCombination therapy (lopinavir/ritonavir)\
Hydroxychloroquine\
RemdesivirWith USA United States of America, interferon-β B1 (Betaseron)Antibiotics\
Oseltamivir\
Hydroxychloroquine (or chloroquine phosphate)\
Azithromycin Hydrocortisone Therapeutic anticoagulants if D-Dimer Invasive

In light of limited evidence in the literature regarding medication used to treat COVID-19, this review aims to retrospectively evaluate the therapeutic management received by patients with COVID-19 since emergence of the virus.

Methods {#sec2}
=======

A systematic review protocol was developed based on PRISMA-P and the PRISMA statement. Articles for review were selected from Embase, Medline and Google Scholar. Readily accessible peer-reviewed, full articles in English, published from 1^st^ December 2019 to 26^th^ March 2020, were included. The search terms included combinations of: COVID-19, SARS-COV-2, glucocorticoids, chloroquine, convalescent plasma, antiviral, antibacterial, oseltamivir, hydroxychloroquine, chloroquine phosphate and monoclonal antibodies. There were no restrictions on the types of study eligible for inclusion; however, these were likely to be quantitative studies and randomized clinical trials. The focus of this review was therapeutics for the management of patients with COVID-19.

The primary outcomes were: (1) evidence of therapeutics used for the management of patients with COVID-19 in clinical practice, irrespective of patient characteristics, setting and outcome measures, in order to discuss the most commonly reported medicines; and (2) clinical outcomes of therapeutic treatment (i.e. recovery, mortality) in patients with COVID-19. The secondary outcome of this review was adverse events associated with treatment.

Duplicate articles were removed. Titles and abstracts were screened independently by two reviewers, followed by review of full articles where any doubt remained. Inclusions and exclusions were recorded following PRISMA guidelines, and detailed reasons for exclusion were recorded. Critical appraisal checklists appropriate to each study design were applied and checked by a second team member. Any bias or quality issues identified were considered prior to a quantitative meta-analysis and meta-narrative. Critical Appraisal Skills Programme checklist tools were used for quality assessment. A data extraction tool was designed to capture focus of interest, population, geographical location, methodology, specific mention of therapeutic treatment and adverse events, key findings and further research. Ethical approval was not required for this review of existing peer-reviewed literature.

Results {#sec3}
=======

Four hundred and forty-nine articles were identified in the literature search. Inclusions and exclusions are reported following PRISMA guidelines in [Figure 1](#fig1){ref-type="fig"} , with reasons for exclusion recorded ([Table II](#tbl2){ref-type="table"} ). In total, 213 duplicate studies were excluded. In addition, 18 studies were excluded due to language (Chinese *N*=9, Dutch *N*=2, Vietnamese *N*=1, Spanish *N*=1, Italian *N*=1, Russian *N*=1, Portuguese *N*=1, Iranian *N*=1, German *N*=1), and 10 studies were excluded for other reasons, including incomplete and irrelevant articles.Figure 1PRISMA flow diagram reporting search results. COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.Figure 1Table IIExcluded papers and reasons for exclusionTable IINo.AuthorsTitleCOVID-19\
Yes/noReason for exclusion1Chughtai et al., 2020Policies on the use of respiratory protection for hospital health workers to protect from coronavirus disease (COVID-19)YesNo details on therapeutics/commentary2Gurwitz, 2020Angiotensin receptor blockers as tentative SARS-CoV-2 therapeuticsYesCommentary3Wang et al., 2020Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroYesCommentary4Colson et al., 2020Chloroquine and hydroxychloroquine as available weapons to fight COVID-19YesCommentary5Liu et al., 2020Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancyYesNo details on therapeutics/commentary6Baron et al., 2020Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?YesCommentary7Mitja and Clotet, 2020Use of antiviral drugs to reduce COVID-19 transmissionYesCommentary8Colson et al., 2020**Chloroquine for the 2019 novel coronavirus SARS-CoV-2**YesCommentary9Morse et al., 2020Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoVYesCommentary10Thevarajan et al., 2020Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19YesCommentary11Elfiky, 2020Anti-HCV, nucleotide inhibitors, repurposing against COVID-19YesCommentary12Ung, 2020Community pharmacist in public health emergencies: quick to action against the coronavirus 2019-nCoV outbreakYesCommentary13Gupta, 2020Clinical considerations for patients with diabetes in times of COVID-19 epidemicYesCommentary14Dong et al., 2020Discovering drugs to treat coronavirus disease 2019 (COVID-19)YesCommentary15Zhang et al., 2020Liver injury in COVID-19: management and challengesYesCommentary16Cunningham et al., 2020Treatment of COVID-19: old tricks for new challengesYesCommentary17Ko et al., 2020Arguments in favour of remdesivir for treating SARS-CoV-2 infectionsYesCommentary18Arabi et al., 2020COVID-19: a novel coronavirus and a novel challenge for critical careYesCommentary19Wang and Shi, 2020Managing neonates with respiratory failure due to SARS-CoV-2YesCommentary20Stebbing et al., 2020COVID-19: combining antiviral and anti-inflammatory treatmentsYesCommentary21Touret and Lamballerie, 2020Of chloroquine and COVID-19YesCommentary22Porcheddu et al., 2020Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and ChinaYesNo therapeutic data/commentary23Zhang et al., 2020Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinicsYesCommentary24Baden and Rubin, 2020COVID-19 -- the search for effective therapyYesCommentary25Baud et al., 2020COVID-19 in pregnant womenYesNo therapeutic data/commentary26Ortega et al., 2020Unrevealing sequence and structural features of novel coronavirus using in silico approaches: the main protease as molecular targetYesNo therapeutic data27Ma et al., 20202019 novel coronavirus disease in hemodialysis (HD) patients: report from one HD center in Wuhan, ChinaYesNo therapeutic data28Columbus et al., 20202019 novel coronavirus: an emerging global threatYesCommentary29Barry et al., 2020COVID-19 in the shadows of MERS-CoV in the Kingdom of Saudi ArabiaYesCommentary30Wang et al., 2020A precision medicine approach to managing 2019 novel coronavirus pneumoniaYesNo therapeutic data/commentary31Singhal, 2020A Review of coronavirus disease-2019 (COVID-19)YesReview article32Li et al., 2020A simple laboratory parameter facilitates early identification of COVID-19 patientsYesRetrospective case-negative control study33Guo et al., 2020A survey for COVID-19 among HIV/AIDS patients in two districts of Wuhan, ChinaYesNo therapeutic data34Gao et al., 2020Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studiesYesCommentary35Deng et al., 2020Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort studyYesRetrospective control study36Murthy et al., 2020Care for critically ill patients with COVID-19YesCommentary37Deng and Peng, 2020Characteristics of and public health responses to the coronavirus disease 2019 outbreak in ChinaYesReview38Wang et al., 2020Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, ChinaYesNo therapeutic data39Xiong et al., 2020Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changesYesNo therapeutic data40Chen et al., 2020Clinical and immunologic features in severe and moderate forms of coronavirus disease 2019YesNo therapeutic data41Chen et al., 2020Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical recordsYesNo therapeutic data42Hong et al., 2020Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and childrenYesPerspectives/no therapeutic data43Ye et al., 2020Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivationYesNo therapeutic data44Anderson et al., 2020Clinical management of suspected or confirmed COVID-19 diseaseYesReview45Zhang et al., 2020Clinical trials for the treatment of coronavirus disease 2019 (COVID-19): a rapid response to urgent needYesCommentary46Chen et al., 2020Convalescent plasma as a potential therapy for COVID-19YesCommentary47Yang et al., 2020Corona virus disease 2019: a growing threat to children?YesCommentary/no therapeutic data48Kooraki et al., 2020Coronavirus (COVID-19) outbreak: what the department of radiology should knowYesCommentary/no therapeutic data49Rasmussen et al., 2020Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to knowYesCommentary/no therapeutic data50Liu et al., 2020Coronavirus disease 2019 (COVID-19) during pregnancy: a case seriesYesNo therapeutic data51Mclntosh et al., 2020Coronavirus disease 2019 (COVID-19)YesReview52He and Li, 2020Coronavirus disease 2019 (COVID-19): what we know?YesReview53Xiong et al., 2020Coronaviruses and the cardiovascular system: acute and long-term implicationsYesCommentary54Gong et al., 2020Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumoniaYesNo therapeutic data55Dong et al., 2020Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in ChinaYesNo therapeutic data56Shereen et al., 2020COVID-19 infection: origin, transmission, and characteristics of human coronavirusesYesReview57Rio and Malani, 2020COVID-19 -- new insights on a rapidly changing epidemicYesReview58Yi et al., 2020COVID-19: what has been learned and to be learned about the novel coronavirus diseaseYesReview59Rezaeetalab et al., 2020COVID-19: a new virus as a potential rapidly spreading in the worldwideYesReview60Shaker et al., 2020COVID-19: pandemic contingency planning for the allergy and immunology clinicYesNo therapeutic data61Aslam and Mehra, 2020COVID-19: yet another coronavirus challenge in transplantationYesCommentary62Padmanabhan, 2020Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with nitazoxanide and hydroxychloroquineYesCommentary63Hick et al., 2020Duty to plan: health care, crisis standards of care, and novel coronavirus SARS-CoV-2YesDiscussion64Yang et al., 2020Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, ChinaYesNo therapeutic data65Khan, 2020Epidemiology of corona virus in the world and its effects on the China economyYesReview66Hoehl et al., 2020Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, ChinaYesCommentary67Yang et al., 2020Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcomeYesReview68Cascella et al., 2020Features, evaluation and treatment of coronavirus (COVID-19)YesReview69Erol, 2020High-dose intravenous vitamin C treatment for COVID-19 (a mechanistic approach)YesReview70Liu et al., 2020Highly ACE2 expression in pancreas may cause pancreas damage after SARS-CoV-2 infectionYesCommentary71Zhang et al., 2020Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19YesNo therapeutic data72Mao et al., 2020Implications of COVID-19 for patients with pre-existing digestive diseasesYesCommentary73Ferguson et al., 2020Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demandYesNo therapeutic data74Qiu et al., 2020Intensive care during the coronavirus epidemicYesCommentary75Poon et al., 2020ISUOG interim guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionalsYesReview76Khan et al., 2020The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic optionsYesDiscussion77Sun et al., 2020Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu ProvinceYesCommentary78Guzzi et al., 2020Master regulator analysis of the SARS-CoV-2/human interactomeYesNo therapeutic data79Memish et al., 2020Middle East respiratory syndromeNoReview80Nicastri, 2020Recommendations for COVID-19 clinical managementYesCommentary81Li et al., 2020Network bioinformatics analysis provides insight into drug repurposing for COVID-2019YesNo therapeutic data82Xiong et al., 2020Novel and potent inhibitors targeting DHODH, a rate-limiting enzymein de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2YesNo therapeutic data83Rezabakhsh et al., 2020Novel coronavirus (COVID-19): a new emerging pandemic threatYesSurvey/no therapeutic data84Ai et al., 2020Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern ChinaYesNo therapeutic data85Qiu et al., 2020Outcome reporting from protocols of clinical trials of coronavirus disease 2019 (COVID-19): a reviewYesNo therapeutic data86Bajema et al., 2020Persons evaluated for 2019 novel coronavirus -- United States, January 2020YesCommentary87Shanmugaraj et al., 2020Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19)YesReview88Zhou and Zhao, 2020Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2YesReview89Hoffmann et al., 2020SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitorYesNo therapeutic data90Zhang and Liu, 2020Potential interventions for novel coronavirus in China: a systematic reviewYesReview91Vasylyeva, 2020Pregnancy and COVID-19: a brief reviewYesReview92Alamri et al., 2020Pharmacoinformatics and molecular dynamic simulation studies reveal potential inhibitors of SARS-CoV-2 main protease 3CLproYesNo therapeutic data93Fisher and Heymann, 2020Q&A: The novel coronavirus outbreak causing COVID-19YesCommentary94Goh et al., 2020Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from COVID-19 infectionYesNo therapeutic data95Chen et al., 2020Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patientsYesNo therapeutic data96Bouadma et al., 2020Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivistsYesReview97Zhu et al., 2020Systematic review of the registered clinical trials of coronavirus disease2019 (COVID-19)YesReview98Yang et al., 2020The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in ChinaYesReview99Li et al., 2020The neuroinvasive potential of SARS CoV2 may play a role in the respiratory failure of COVID 19 patientsYesReview100Naicker et al., 2020The novel coronavirus 2019 epidemic and kidneysYesReview101Fang et al., 2020Transmission dynamics of the COVID 19 outbreak and effectiveness of government interventions: a data driven analysisYesNo therapeutic data102Sun et al., 2020Understanding of COVID 19 based on current evidenceYesReview103Wang et al., 2020Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measuresYesReview104Maoujoud et al., 2020What nephrologist should know about COVID-19 outbreak?YesCommentary105Cortegiani et al., 2020A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19YesReview106Ryu et al., 2020An interim review of the epidemiological characteristics of 2019 novel coronavirusYesReview107Yang and Shen, 2020Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19YesReview108Fan et al., 2020Bat coronaviruses in ChinaYesReview109Russell et al., 2020Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injuryYesCommentary110Liang et al., 2020Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cellsYesNo therapeutic data/commentary111Wu et al., 2020Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, ChinaYesCommentary112Martinez et al., 2020Compounds with therapeutic potential against novel respiratory 2019 coronavirusYesCommentary113Tang et al., 2020Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patientYesNo therapeutic data114Chang et al., 2020Coronavirus disease 2019: coronaviruses and blood safetyYesReview115Walker, 2020COVID-19, Australia: Epidemiology Report 2YesCommentary116Lu, 2020Drug treatment options for the 2019-new coronavirus (2019-nCoV)YesCommentary117Hellewell et al., 2020Feasibility of controlling COVID-19 outbreaks by isolation of cases and contactsYesNo therapeutic data118Prompetchara et al., 2020Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemicYesReview119Ashour et al., 2020Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaksYesReview120Zhou et al., 2020Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2YesNo therapeutic data121Devaux et al., 2020New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?YesReview122Cauchi and Locht, 2020Non-specific effects of live attenuated pertussis vaccine against heterologous infectious and inflammatory diseasesYesReview123Chang et al., 2020Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase dockingYesNo therapeutic data124Pang et al., 2020Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic reviewYesReview125Chen et al., 2020Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case reportYesCommentary126Liu et al., 2020Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseasesYesReview127Gralinski and Menachery, 2020Return of the coronavirus: 2019-nCoVYesCommentary128Cao et al., 2020SARS-CoV-2 infection in children: transmission dynamics and clinical characteristicsYesCommentary129Walls et al., 2020Structure, function and antigenicity of the SARS-CoV-2 spike glycoproteinYesCommentary130Xu et al., 2020Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-YesReview131Garrett, 2020The art of medicine COVID-19: the medium is the messageYesCommentary132Habibzadeh and Stoneman, 2020The novel coronavirus: a bird\'s eye viewYesReview133Wu et al., 2020The SARS-CoV-2 outbreak: what we knowYesReview134Nezhad et al., 2020Therapeutic approaches for COVID-19 based on the dynamics of interferon-mediated immune responsesYesNo therapeutic data135Lu, 2020Timely development of vaccines against SARS-CoV-2YesCommentary136Kim et al., 2020Viral load kinetics of SARS-CoV-2 infection in first two patients in KoreaYesCommentary137Sekhar, 2020Virtual screening based prediction of potential drugs for COVID-19YesNo therapeutic data138Park et al., 2020Virus isolation from the first patient with SARS-CoV-2 in KoreaYesCommentary139Lake, 2020What we know so far: COVID-19 current clinical knowledge and researchYesReview140Ralph et al., 20202019-nCoV (Wuhan virus), a novel coronavirus: human-to-human transmission, travel-related cases, and vaccine readinessYesReview141Jin, 2020A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)YesReview142Liu et al., 2020Association of cardiovascular manifestations with in-hospital outcomes in patients with COVID-19: a hospital staff dataYesNo therapeutic data143Lai et al., 2020Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and mythsYesReview144Bordi et al., 2020Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020YesCommentary145Li, 2020Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)YesReview146Song and Karako, 2020COVID-19: real-time dissemination of scientific information to fight a public health emergency of international concernYesCommentary147Vankadari and Wilce, 2020Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26YesReview148Hsih et al., 2020Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central TaiwanYesNo therapeutic data149Stoecklin et al., 2020First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020YesNo therapeutic data150Chan et al., 2020Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting WuhanYesNo therapeutic data151Boulos and Geraghty, 2020Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemicsYesNo therapeutic data152Zeng et al., 2020Mortality of COVID-19 is associated with cellular immune function compared to immune function in Chinese Han populationYesNo therapeutic data153Ahmed et al., 2020Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studiesYesNo therapeutic data154Lai et al., 2020Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challengesYesReview155Alhazzani et al., 2020Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)YesNo therapeutic data156Guo et al., 2020The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -- an update on the statusYesReview157Yang et al., 2020Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspectiveYesReview158Liu et al., 2020Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunctionYesNo therapeutic data159World Health Organization, 2020Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspectedYesGuidelines160Li et al., 2020Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosisYesNo therapeutic data161Mao et al., 2020Clinical and pathological characteristics of 2019 novel coronavirus disease (COVID-19): a systematic reviewsYesReview162Cui et al., 2020Clinical features and sexual transmission potential of SARS-CoV-2 infected female patients: a descriptive study in Wuhan, ChinaYesNo therapeutic data163Saw Swee Hock School of Public Health, 2020COVID-19 science report: therapeuticsYesReport164Yao, 2020In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)YesCommentary165Pongpirul et al., 2020Journey of a Thai taxi driver and novel coronavirusYesNo therapeutic data166Liu et al., 2020A locally transmitted case of SARS-CoV-2 infection in TaiwanYesNo therapeutic data167Velavan and Meyer, 2020The COVID-19 epidemicYesCommentary

Consensus on final inclusion of studies (*N*=41) (negotiated without the need for a third reviewer) is presented in [Table III](#tbl3){ref-type="table"} .Table IIIData extracted from included papersTable IIIAuthor/title/DOISample sizeMean age (years)GenderType of studyTherapeutic treatmentType: *N* (%)Outcomes (recovery/mortality)Adverse eventsQuality assessment (applicable/inapplicable)1Cao *et al.* A trial of lopinavir--ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020. <https://doi.org/10.1056/NEJMoa2001282>19958120 M\
79 FRandomized clinical trialLopinavir and ritonavirLopinavir and ritonavir: 50%Standard care: 50%In hospitalized adult patients with severe COVID-19, no benefit was observed with lopinavir--ritonavir treatment beyond standard careNineteen deaths among patients who received the intervention14% of patients who received lopinavir--ritonavir developed gastrointestinal adverse events, including anorexia, nausea, abdominal discomfort or diarrhoea, as well as two serious adverse events (both acute gastritis)Two recipients had self-limited skin eruptionsThe study addressed a focused issue\
Randomization with intention-to-treat analysis\
The population who entered the study were accounted for properly in the conclusion\
Not blinded\
The two groups who entered the study were similar and treated equally\
The primary outcome was specified clearly2Cao *et al.* Clinical features and short-term outcomes of 18 patients with coronavirus disease 2019 in intensive care unit. Intensive Care Med 2020.<https://doi.org/10.1007/s00134-020-05987-7>414930 M\
11 FProspectiveAntibiotics and oseltamivir (orally 75 mg twice daily)Corticosteroid was given as a combined regimen if severe community-acquired pneumonia was diagnosed by physicians at the designated hospitalAll patients received empirical antibiotic treatmentAntiviral (oseltamivir): 38 (93%)Systemic corticosteroid: 9 (22%)Antiviral: 12 ICU admissions (92%)\
Antibiotic: 13 ICU admissions (100%)\
Corticosteroid: six ICU admissions (46%)Not reportedAdverse events not reported\
Treatment given not specified\
Types of antibiotics given not mentioned3Chen *et al.* Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv 2020. <https://doi.org/10.1101/2020.03.17.200>23656 (25--86)Favipiravir group:59 M\
57 FArbidol group:51 M\
69 FRandomized controlled trialFavipiravir\
ArbidolAntiviral: 116\
Antiviral: 12071 patients recoveredAbnormal liver function tests, raised serum uric acid, psychiatric symptom reactions and digestive tract reactionsNo effective antiviral drug was reported, and the drugs mentioned were based on the sixth edition of the guidelines of Chinese diagnosis and treatment plan of COVID-19 patients4Chen *et al.* Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia 2020. Preprints 2020; 2020020395. <https://www.preprints.org/manuscript/202002.0395/v1>145FCase reportThalidomide and low-dose glucocorticoid. The patient was first treated with oral ofloxacin and oseltamivir, but her condition deteriorated. The patient was subsequently treated with lopinavir/ritonavirThalidomide inhibits the cytokine surge and regulates immune functions. In addition, it can be used to calm patients down in order to reduce oxygen consumption and relieve digestive symptomsNot reportedRandomized controlled trials are needed5Chen *et al.* Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering 2020. <https://doi.org/10.1016/j.eng.2020.02.006>6162Not mentionedOpen labelled clinical trialOseltamivir or peramivir (according to standard therapy) and antibiotics were given based on positive blood test resultsNot mentioned17.6% of patients in the experimental group and 54.5% of patients in the control group diedNot reportedWith only 17 patients using mesenchymal stem cells, it cannot be guaranteed that every step was perfect during the phase with a single clinical trialSome patients refused to attend and some did not complete follow-up. Thus, there is still concern about the long-term safety of mesenchymal stem cell transplantation for the treatment of H7N9-induced ARDS, despite the lack of side-effects observed in this clinical trial This study was undertaken on patients with H7N9 not COVID-196Chen *et al.* Retrospective analysis of clinical features in 101 death cases with COVID-19. medRxiv 2020. <https://doi.org/10.1101/2020.03.09.20033068>10165.4664 M\
37 FSingle centre and observational study (retrospective)Antiviral drugs, including oseltamivir, ribavirin, lopinavir, ritonavir, ganciclovir and interferon\
Glucocorticoids, IV immunoglobulins and thymosin preparations\
\
Antibiotic treatment, including cephalosporins, quinolones, carbapenems, linezolid and tigecyclineAntiviral: 61 (60.4%) Glucocorticoid: 59 (58.42%)IV immunoglobulin: 63.37%\
Thymosin: 44.55%Antibiotic: 101 (100%)Restricted antibiotic: 63 (62.38%)Antifungal: 23 (22.78%)101 patients diedNot reportedOnly the critical death patients are included No comparison was made between the improvement groups7Chen *et al.* Clinical progression of patients with COVID-19 in Shanghai, China. J Infect 2020. <https://doi.org/10.1016/j.jinf.2020.03.004>24951126 M\
123 FRetrospective, single-centre studyAntiviral drugs (e.g. lopinavir/ritonavir, arbidol) were used in a small proportion of patients Corticosteroids were not used unless considered necessary by an expert panel (e.g. ARDS)Not mentionedTwo patients died (0.8%)\
22 patients were admitted to ICU (8.8%)\
Eight patients developed ARDS (3.2%)\
215 patients were discharged (86.3%)Not reportedA small proportion the patients were still hospitalized at the time of manuscript submission. Therefore, clinical outcomes in these patients were not available and continued observations are needed SARS-CoV-2 was not tested daily for all patients. Hence, the actual time to viral clearance should be shorter than the estimated value8Chen *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507--13.9955.567 M\
32 FRetrospective, single-centre descriptive studyAntibiotic: cephalo-sporins, quinolones, carbapenems, tigecycline against meticillin-resistant *Staphylococcus aureus*, linezolid\
Antifungal\
Antiviral: oseltamivir, ganciclovir and lopinavir/ritonavir\
Glucocorticoid: methylprednisolone sodium succinate, methylprednisolone and dexamethasone-\
ImmunoglobulinAntibiotic: 70 (71%)\
Antifungal: 15 (15%)\
Antiviral: 75 (76%), including oseltamivir (75 mg every 12 h, orally), ganciclovir (0.25 g every 12 h, intravenously), and lopinavir/ritonavir (500 mg twice daily, orally). The duration of antiviral treatment was 3--14 days\
Glucocorticoid: 19 (19%)\
\
IV immunoglobulin: 27 (27%)11 (11%) patients diedNot reported or NASuspected but undiagnosed cases were ruled out in the analyses More detailed patient information, particularly regarding clinical outcomes, was unavailable at the time of analysis9Chen *et al.* Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. medRxiv 2020. <https://doi.org/10.1101/2020.03.03.20030353>29146145 M\
146 FDouble-centre observational studyAntiviral including lopinavir and ritonavir Recombinant human interferon-α2b Recombinant cytokine gene-derived protein Arbidol hydrochloride Chinese medicineAntiviral: 285 (97.9%)Lopinavir/ritonavir: 75.9% Recombinant human interferon-α2b: 45.4% Recombinant cytokine gene-derived protein: 18.9%\
\
Arbidol hydrochloride: 17.2%\
\
Chinese medicine: 281 (96.6%)Two (0.7%) patients diedNot reportedDue to limitations of the retrospective study, laboratory examinations were performed according to the clinical care needs of the patients; as such, some laboratory examinations were not completed Given the short observation period, nearly half of the patients were still receiving treatment in hospital at the end of the follow-up period, and it was not possible to determine mortality and prognosis of the whole case series10Cui *et al.* A 55-day-old female infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage. J Infect Dis 2020. <https://doi.org/10.1093/infdis/jiaa113>155 daysFCase reportInhaled interferon-α1b (15 μg, bid); amoxicillin potassium clavulanate (30 mg/kg, Q8H, ivgtt)NANANACase report for infant patient\
Adverse events and outcomes not reported11Du *et al.* Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. SSRN 2020. <https://ssrn.com/abstract=3546088>19156119 M\
72 FRetrospective, multi-centre cohort studyAntibiotic\
Antiviral (lopinavir and ritonavir)\
Corticosteroid\
\
\
IV immunoglobulinAntibiotic: 181 (95%)\
Antiviral (lopinavir and ritonavir): 41 (21%)\
Corticosteroid: 57 (30%)\
\
\
IV immunoglobulin: 46 (24%)181 (95%) patients received antibiotics: 53 (98%) died, 128 (93%) survived (*P*=0.15)\
41 (21%) patients received antivirals: 12 (22%) died, 29 (21%) survived (*P*=0.87)\
57 (30%) patients received corticosteroid: 26 (48%) died, 31 (23%) survived (*P*=0.0005)\
46 (24%) patients received IV immunoglobulin: 36 (67%) died, 10 (7%) survived (*P*\<0.0001)\
54 patients died in hospitalNot reportedLack of effective antivirals, inadequate adherence to standard supportive therapy, and high-dose corticosteroid use may also have contributed to the poor clinical outcomes in some patients12Gautret *et al.* Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949. <https://doi.org/10.1016/j.ijantimicag.2020.105949>Treated: 20\
Control: 16\
Total: 3645.115 M\
21 otherOpen label non- randomized clinical trialHydroxychloroquine and azithromycinHydroxychloroquine sulfate 200 mg, three times per day for 10 daysOn day 6 post inclusion, 100% of patients treated with a combination of hydroxychloroquine and azithromycin were virologicaly cured, compared with 57.1% of patients treated with hydroxychloroquine alone and 12.5% of patients in the control groupOne patient stopped treatment on day 3 post inclusion due to nauseaClinical follow-up and occurrence of side-effects were not discussed13Guan *et al.* Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. <https://doi.org/10.1056/NEJMoa2002032>109947.941.1% FRetrospective observational studyIV antibiotic\
Oseltamivir\
Antifungal\
Systemic glucocorticoidAntibiotic: 637 (58%)\
Oseltamivir: 393 (35.8%)\
Antifungal: 31 (2.8%)\
Glucocorticoid: 204 (18.6%)5.0% of patients were admitted to the ICU, 2.3% underwent invasive mechanical ventilation and 1.4% died among the 173 patients with severe diseaseNot reportedDrug dose, frequency and duration were not included14Holshue *et al.* First case of 2019 novel coronavirus in the United States. N Engl J Med 2020. <https://doi.org/10.1056/NEJMoa2001191>135MCase reportAntipyretic consisting of guaifenesin650 mg\
600 mgDischarged with no symptomsNot reportedThis was only a single case study and does not represent the whole population\
As this was a case report, it is not certain that the positive impact on the patient\'s health was due to the medication taken\
Randomized controlled trials are needed15Huang *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497--506.414930 M (73%)\
11 F (27%)Prospective collection and analysed data for patients with pneumoniaAntiviral: 38 (93%)\
Antibiotic: 41 (100%)\
Corticosteroid: 9 (22%)Not mentionedOne patient was admitted to ICU\
Six patients diedNot reportedAs the causative pathogen has just been identified, kinetics of viral load and antibody titres were not available at the time of the study16Huang *et al.* Early and critical care in severe patients with COVID-19 in Jiangsu Province, China: a descriptive study. 2020. <https://doi.org/10.21203/rs.3.rs-17397/v1>605758.3% M\
42.8% otherMulti-centre retrospective cohort study was conducted to extract and analyse epidemiological, clinical and laboratory data and treatment of 60 severe casesAntiviral: 60 (100%)\
Abidor: 50 (83.3)\
Lopinavir/ritonavir: 41 (68.3)\
Interferon: 12 (20.0)\
Ribavirin: 7 (11.7)\
Oseltamivir: 2 (3.3)\
Fluoroquinolone: (61.7%)34 patients (56.7%) received IV glucocorticoids at doses ranging from 40 to 80 mg/day\
28 patients (46.7%) received immunoglobulin (IgG enriched) injections for 5--9 days of immunoregulation50 patients improved significantly\
Two patients were discharged\
Eight patients remained in a serious conditionFour patients who developed secondary infections received glucocorticoidsMost drug doses, frequencies and durations were not included\
The effect of glucocorticoids was not significant17Huang *et al.* Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv 2020. <https://doi.org/10.1101/2020.02.27.20029009>3669.2225 M (69.44%)\
11 F (30.56%)Retrospective, single-centre studyAntibiotic: 36 (100%)\
Antiviral: 35 (97.22%)\
Glucocorticoid: 25 (69.44%)Not mentionedAll patients diedAll patients diedDrug dose, frequency and duration were not included18Jian-ya G. Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China. medRxiv 2020. <https://doi.org/10.1101/2020.02.20.20025536>514532 M (62.7%)\
19 F (37.3%)Retrospective, single-centre case seriesOseltamivir (oral): 7 (13.7%)\
Interferon (oral): 51 (100%)\
Kaletra (oral): 51 (100%)\
Thymopentin (IM): 48 (94.1%)\
Traditional Chinese medicine decoction (oral): 28 (54.9%)\
Reduling (IV): 30 (58.8%)\
Xuebijing (IV): 2 (3.9%)Not mentionedOne patient died with shock complicationsSix patients had an obvious decline in appetite\
.Drug dose, frequency and duration were not included19Liang *et al.* Clinical characteristics of 457 cases with coronavirus disease 2019. Available at SSRN. 2020. <https://doi.org/10.2139/ssrn.3543581>457Varies267 M (58%)\
9 pregnant women (2%)Systematic reviewAntiviral: 352 (77%)\
Antibacterial:\
258 (56%)\
Glucocorticoid:\
130 (28%)Not mentioned195 patients improved and were discharged35 patients diedDrug dose, frequency and duration were not included20Liao *et al.* Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. medRxiv 2020. <https://doi.org/10.1101/2020.03.10.20032136>46Not mentioned because they were two groups17 M (53.1)\
15 F (46.9)Retrospective case series dataAntiviral: 46 (100.0%)\
Antifungal: 5 (10.9%)\
GlucocorticoidNot mentioned78.3% of patients were dischargedThree patients developed acute kidney injury during treatmentAt the end of this study, nearly 20% of the patients were still hospitalized21Lim *et al.* Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020; 35. <https://doi.org/10.3346/jkms.2020.35.e79>154MCase reportLopinavir/ritonavir200 mg\
50 mg\
(two tablets bid)Reduced viral load and improved clinical symptomsThe patient also complained of psychiatric symptoms such as depression, insomnia and suicidal thoughts after isolationThis was a single case and does not represent the whole population\
Randomized controlled trials are needed22Liu *et al.* Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020. <https://doi.org/10.1016/j.ijid.2020.03.013>10426 F\
4 otherRetrospective observational single-centre studyLopinavir,\
Interferon-α2b atomization inhalation400 mg every\
twelve hoursOeosinophil counts presented potential as predictor of the development of COVID-19\
Seven patients were discharged\
Three patients stopped lopinavir: two deteriorated and one was hospitalized for longer than other patients who continued taking lopinavirDigestive adverse effect and hypokalaemiaSmall sample size23Liu *et al.* Epidemiological, clinical characteristics and outcome of medical staff infected with COVID-19 in Wuhan, China: a retrospective case series analysis. medRxiv 2020. <https://doi.org/10.1101/2020.03.09.20033118>6435 (29--43)23 M\
41 FSingle centre- retrospective-observational studyImmunoglobulin Thymosin CorticosteroidAntibody: 23 Hormone: 33 Steroid hormone: 734 patients were discharged\
30 patients were still hospitalizedNot reportedPreliminary insight into epidemiological features and clinical outcomes Single centre24Liu *et al.* Detection of COVID-19 in children in early January 2020 in Wuhan, China. N Engl J Med 2020. <https://doi.org/10.1056/NEJMc2003717>Six3 (1--7)2 M\
4 FRetrospective case series analysisRibavirin\
Oseltamivir\
Glucocorticoid\
IV immunoglobulinAntiviral: 2\
Antiviral: 6\
Steroid hormone: 4\
Antibody: 1Six patients recoveredNot reportedSmall sample size25Liu *et al.* Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv 2020. <https://doi.org/10.1101/2020.02.17.20024166>1095559 M\
50 FRetrospective case series analysisGlucocorticoid IV immunoglobulinSteroid hormone: 43\
\
Antibody: 32\
Antibiotic: 105\
Antiviral: 10531 patients diedNot reportedThis study did not mention the names of the therapeutic treatment used among patients with ARDS26Lo *et al.* Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci 2020; 16:1698--707. <https://doi.org/10.7150/ijbs.45357>1054 (27--64)3 M\
1 teenager\
6 otherRetrospective case series analysisLopinavir\
RitonavirAntiviral: 10Five patients were discharged\
Five patients were still hospitalizedNot reportedSmall sample size, so difficult to draw a definite conclusion Single centre Half of the enrolled patients were still hospitalized at the time of submission of this paper. Therefore, there may have been bias regarding the prognosis of the patients27Mo *et al.* Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020. <https://doi.org/10.1093/cid/ciaa270>15554 (42--66)86 M\
69 otherSingle-centre, retrospective case series analysisArbidol\
Lopinavir and ritonavir\
Interferon inhalation\
Immune enhancerAntiviral: 31\
Antiviral: 27\
\
\
Antiviral: 30\
\
Immune enhancer: 1422 patients diedNot reportedSelection bias may have occurred, and a large-scale nationwide study is needed28Wang *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. <https://doi.org/10.1001/jama.2020.1585>13856 (42--68)75 M\
63 FRetrospective, single-centre case seriesOseltamivir\
Moxifloxcain\
Ceftriaxone\
Azithromycin\
GlucocorticoidAntiviral: 124\
Antibacterial: 89\
Antibacterial: 34\
Antibacterial: 25\
Glucocorticoid: 6247 patients were discharged\
Six patients died\
85 patients were still hospitalizedNot reportedMost patients were still hospitalized at the time of manuscript submission. Therefore, there may have been bias regarding the prognosis of the patients.29Wang *et al.* Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020. <https://doi.org/10.1093/cid/ciaa272>6942 (35--62)32 M\
37 FRetrospective case series-Antiviral: 66\
Antibiotic: 66\
Antifungal: 8\
Corticosteroid: 10\
Arbidol: 3644 patients were still hospitalized\
18 patients were discharged\
Five patients diedNot reportedDrug dose, frequency and duration were not included30Wu *et al.* Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19). medRxiv 2020. <https://doi.org/10.1101/2020.02.26.20028589>18852119 M\
69 otherRetrospective cohort study-Antibiotic: 185\
Antiviral: 158\
Corticosteroid: 5943 patients died\
145 patients were discharged\
12 patients were still hospitalizedNot reportedDrug dose, frequency and duration were not included31Wu F *et al.* A new coronavirus associated with human respiratory disease in China. Nature 2020; 579:265--9.141MEpidemiological investigationsAntiviral\
Antibiotic\
Glucocorticoid\
OxygenOseltamivir\
Cefoselis\
Not mentioned\
Mechanical ventilationRecoveredNot reportedApplicable32Xu *et al.* Clinical characteristics of SARS-CoV-2 pneumonia compared to controls in Chinese Han population. medRxiv 2020. <https://doi.org/10.1101/2020.03.08.20031658>Patients: 69\
Controls: 14,1175750.7% M\
49.3% FRetrospective, multi-centre case seriesAntiviral\
Antibiotic\
OxygenOseltamivir: 38 (55.1%)\
Moxifloxacin, ceftriaxone, azithromycin, tigecycline or linezolid:\
31 (44.9%)\
Mechanical ventilation: 2\
Invasive ventilator: 2Three patients were discharged\
One patient recovered\
One patient diedSix patients with a significant increase in IL6 were also treated with methylprednisoloneApplicable33Xu *et al.* Clinical findings in critical ill patients infected with SARS-CoV-2 in Guangdong Province, China: a multi-center, retrospective, observational study. medRxiv 2020. <https://doi.org/10.1101/2020.03.03.20030668>4556.729 M (64.4%)\
16 F (35.6%)Multi-centre, retrospective, observational studyAntiviral: 45 (100) patients\
Antibacterial: 45 (100)\
Antifungal: 19 (42.2)\
Convalescent plasma: 6 (13.3)\
Glucocorticoid: 21 (46.7)\
Immunoglobulin: 28 (62.2)\
Albumin: 35 (77.8)Osehamivir ribavirin\
Not mentioned\
Not mentioned\
Not mentioned\
Not mentioned\
Not mentioned\
Not mentioned23 (51.1%) patients were discharged from the ICU\
11 (24.2%) patients were discharged\
One (2.2%) patient died37 (82.2%) patients developed ARDS and 13 (28.9%) patients developed septic shock\
20 (44.4%) patients required intubation and nine (20%) patients required extracorporeal membrane oxygenationAt the time of study submission, half of the patients had not been discharged from the ICU; as such, it was difficult to estimate ICU stay, ventilation-free days, case fatality rate and the predictors of fatality\
Drug dose, frequency and duration were not included34Xu *et al.* Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368:m606.624135 M (56%)\
27 F (44%)Retrospective studyAntiviral: 55 (89%)\
Antibiotic\
Corticosteroid and gamma globulinInterferon-α inhalation: 8 (13%)\
Lopinavir/ritonavir: 4 (6%)\
Arbidol + interferon-α inhalation: 1 (2%)\
Lopinavir/ritonavir + interferon-α inhalation: 21 (34%)\
Arbidol + lopinavir/ritonavir: 17 (28%)\
Arbidol + lopinavir/ritonavir + interferon-α inhalation: 4 (6%)\
28 (45%)\
16 (26%)No deathsNot reportedAt the time of study submission, most patients had not been discharged, so it was difficult to estimate the case fatality rate or the predictors of fatality35Xu *et al.* Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020. <https://doi.org/10.1016/S2213-2600(20)30076-X>150MPostmortem biopsiesAntiviral\
Antibiotic\
CorticosteroidInterferon-α2b atomization\
Lopinavir + ritonavir\
Moxifloxacin\
MethylprednisoloneDied due to cardiac arrestChest x-ray showed progressive infiltrate and diffuse gridding shadow in both lungs. Hypoxaemia and shortness of breath worsened and patient had sudden cardiac arrestThis was a single case study and does not represent the whole population\
The patient refused ventilator support in the ICU repeatedly because he suffered from claustrophobia; therefore, he received high-flow nasal cannula\
There is a need for randomized controlled trials36Yang *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020. <https://doi.org/10.1016/S2213-2600(20)30079-5>5259.735 M (67%)\
17 F (33%)Single-centre retrospective, observational studyVasoconstrictor\
Antiviral:\
23 (44%)\
\
Antibacterial\
Glucocorticoid\
Immunoglobulin18 (35%)\
Oseltamivir: 18 (35%)\
Ganciclovir: 14 (27%)\
Lopinavir: 7 (13.5%).\
49 (94%)\
30 (58%)\
28 (54%)32 (61.5%) patients diedNot reportedDue to the exploratory nature of the study, which was not driven by formal hypotheses, the sample size calculation was waived\
The researchers acknowledged that some specific information from the ICU was missing, such as mechanical ventilation settings\
Drug dose, frequency and duration were not included37Young *et al.* Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020. <https://doi.org/10.1001/jama.2020.3204>18479 M (50%)\
9 F (50%)Descriptive case seriesAntiretroviral\
Antiviral\
AntibioticLopinavir/ritonavir\
Oseltamivir\
Not reportedNo deathsNot reportedSmall sample size\
Drug dose, frequency and duration were not included38Zhang *et al.* Clinical characteristics of 82 death cases with COVID-19. medRxiv 2020. <https://doi.org/10.1101/2020.02.26.20028191>8272.565.9% MDeath casesAntiviral\
Antibiotic\
Corticosteroid82 (100%)\
82 (100%)\
29 (35.3%)Not reportedThe study was performed in one setting. No information was given about the hospital\'s capabilities in terms of personnel or equipment because the mortality rate from this centre was a little higher than other centres\
Traditional Chinese medicine was given\
Drug dose, frequency and duration were not included39Zhang *et al.* Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China. medRxiv 2020. <https://doi.org/10.1101/2020.03.02.20030452>22155108 M (48.9%)\
113 F (51.1%)Retrospective case studyAntiviral:\
196 (88.7%)\
Antibiotic\
Corticosteroid: 115 (52.0%)Oseltamivir\
Arbidol hydrochloride\
Interferon-α atomization inhalation\
Lopinavir/ritonavir\
Moxifloxacin hydrochloride\
Piperacillin sodium tazobactam sodium\
Cefoperazone sulbactam\
Glucocorticoid: 64 (49.6%)12 (5.4%) patients diedNot reportedThe dose and duration of IV glucocorticoid treatment showed no difference in symptomatic relief and death\
Drug dose, frequency and duration were not included40Zhang *et al.* The potential role of IL-6 in monitoring coronavirus disease 2019. <https://doi.org/10.1101/2020.03.01.20029769>805346 F (57.5%)\
34 M (42.5%)Data collection (clinical data from patients with COVID-19 diagnosed by laboratory test in study institution)\
Observation of clinical manifestationAntibiotic: 73 (91.25%)\
Oseltamivir: 20 (25%)\
Ribavirin, ganciclovir or peramivir: 47 (58.75%)\
Arbidol: 49 (61.25%)\
Antifungal: 10 (12.5%)\
IV immunoglobin: 36 (45%)\
Corticosteroid: 29 (36·25%)Not mentionedIL-6 may be used as a biomarker for disease monitoring in severe cases of COVID-19Not reportedDrug dose, frequency and duration were not included\
IL-6 and the pathogenesis of COVID-19 remains elusive41Zhou *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020. <https://doi.org/10.1016/S0140-6736(20)30566-3>19156119 M (62%)\
72 F (38%)Retrospective cohort studyAntibiotic: 181 (95%)\
Antiviral:\
41 (21%)\
Corticosteroid: 57 (30%)\
IV immunoglobin:\
46 (24%)Lopinavir/ritonavir137 patients were discharged\
54 patients died191 patientsThere was no observation of a shortening of the duration of viral shedding after lopinavir/ritonavir treatment\
Drug dose, frequency and duration were not included[^1]

Forty-one studies were included in this review. These were clinical trials (*N*=3), case reports (*N*=7), case series (*N*=10), and retrospective (*N*=11) and prospective (*N*=10) observational studies. Thirty-six studies were conducted in China, and one in each of Korea, the USA, France, Singapore and Macau.

Patient characteristics {#sec3.1}
-----------------------

In total, 8806 patients were reported in the 41 studies included in this review. The mean age of patients was 50.8 years based on 39 studies; age was not specified in two studies.

Reported therapeutics {#sec3.2}
---------------------

Corticosteroids, an anti-inflammatory medication, were reported most commonly in this systematic review (*N*=25), using different names and product characteristics (corticosteroid *N*=21, methylprednisolone *N*=3, dexamethasone *N*=1). Use of lopinavir, an antiviral HIV medication (*N*=21) -- in combination with ritonavir (*N*=18) or alone (*N*=3) -- oseltamivir (*N*=16) and arbidol hydrochloride (*N*=8) was also reported.

In terms of antibacterial agents, moxifloxacin (*N*=4) and tigecycline were reported most frequently.

Convalescent plasma therapy was reported in one multi-centre retrospective observational study of six patients.

Treatment outcome {#sec3.3}
-----------------

The outcome measures recorded were patient discharge and recovery, ongoing hospitalization and mortality ([Table III](#tbl3){ref-type="table"}).

Discussion {#sec4}
==========

To the authors\' knowledge, this is the first systematic review related to medication used to treat patients with COVID-19. Only 41 eligible research articles were identified and included in this review \[[@bib2],[@bib5],[@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49]\]. Of these, three studies were clinical trials; the rest were case reports, case series, or prospective or retrospective observational studies. Systemic corticosteroids with different names and formulations were reported most frequently, followed by the antivirals lopinavir, oseltamivir and arbidol hydrochloride. Convalescent plasma therapy was reported in one multi-centre retrospective observational study and was administered to six patients.

Although quality assessment was applied to the research articles included in this review, there was insufficient evidence to conduct a meta-analysis, and it was not possible to conduct subgroup analysis (adults and children; different formulations, dosages and durations).

Most studies included in this review were of low quality, with incomplete or inconsistent information on study design and outcome. As such, it was difficult to analyse the medication in terms of efficacy and safety.

Despite these limitations, this is the first systematic review on medication used to treat patients with COVID-19, and provides up-to-date insight on the current therapeutic guidelines for management of these patients. Most of the medications reported in this review are available in the USA, Saudi Arabia, Europe and Egypt ([Table I](#tbl1){ref-type="table"}).

Corticosteroids were the most commonly reported medication in this review; however, they are not recommended in any guidelines. In the absence of conclusive scientific evidence, WHO and the US Centers for Disease Control and Prevention (CDC) have recommended that corticosteroids should not be used routinely in patients with COVID-19 for treatment of viral pneumonia or acute respiratory distress syndrome (ARDS) unless indicated for other conditions, such as asthma or chronic obstructive pulmonary disease exacerbation, or septic shock \[[@bib5],[@bib50],[@bib51]\]. Careful use of low-to-moderate doses of corticosteroids as a short course is advised. Hyperglycaemia, hypernatraemia and hypokalaemia are the most common adverse effects associated with the use of corticosteroids and should be monitored routinely \[[@bib5],[@bib51]\].

Lopinavir/ritonavir (Kaletra) was the second most commonly reported medication in this review. A randomized clinical trial reported that this HIV treatment had negative outcomes for patients with COVID-19 ([Table II](#tbl2){ref-type="table"}) \[[@bib30],[@bib52], [@bib53], [@bib54]\]. No benefit of lopinavir/ritonavir treatment compared with standard care was observed in this study, and 19 patients who received the intervention died. However, some study limitations were observed, including lack of blinding. RCT NCT04252885 and the SOLIDARITY trial are ongoing to determine the efficacy of lopinavir/ritonavir in patients with COVID-19 \[[@bib52]\].

Oseltamivir (Tamiflu), used to treat influenza A and influenza B, was the third most commonly reported medication in this review. Oseltamivir has been recommended by WHO for people at high risk of infection for prevention of pandemic influenza. A retrospective observational study reported the use of oseltamivir in 1099 patients with COVID-19; however, the study was not able to provide any solid data on the effectiveness of oseltamivir in the prevention or treatment of COVID-19. Study limitations included incomplete documentation of patient data and recall bias \[[@bib55],[@bib56]\].

Arbidol hydrochloride was the fourth most commonly reported medication in this review. It is a broad-spectrum inhibitor of influenza A and B virus, parainfluenza virus and other viruses, including hepatitis C virus. Arbidol hydrochloride is used in Russia and China, but has not yet been approved for use in other countries \[[@bib52]\]. However, no conclusive evidence of its efficacy in patients with COVID-19 was reported. In this review, it was reported together with favipiravir, which was approved for the treatment of novel influenza on 15^th^ February 2020 in China \[[@bib52]\].

Chloroquine phosphate and hydroxychloroquine were reported in this review and showed favourable outcomes in the recovery of patients with COVID-19 \[[@bib6],[@bib7],[@bib57], [@bib58], [@bib59], [@bib60]\]. These two medications are likely to share the same mechanism of action. Chloroquine, an antimalarial, has shown positive outcomes in patients with COVID-19. Furthermore, hydroxychloroquine has shown significant effectiveness against intracellular pathogens such as *Coxiella burnetii*, the agent of Q fever \[[@bib22]\]. This French open label, non- randomized clinical trial was promising and the first clinical trial of these medications in patients with COVID-19. The effect of hydroxychloroquine was significant because it showed a reduction in the viral load compared with the control group \[[@bib22]\]. Moreover, the effect of hydroxychloroquine was significantly more potent when given in conjunction with azithromycin. However, clinical follow-up and the occurrence of adverse effects were not discussed in the study, and further work is needed to reduce the morbidity and mortality of COVID-19 \[[@bib57], [@bib58], [@bib59]\]. Although chloroquine and hydroxychloroquine have shown promising activity against SARSCoV-2, there is a risk of arrhythmia associated with their administration. Therefore, caution is required for use at higher cumulative dosages. It is recommended that their use in cases of suspected/confirmed COVID-19 should be restricted to hospitalized patients. On 30^th^ March 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization for chloroquine and hydroxychloroquine to treat patients hospitalized with COVID-19 \[[@bib60]\].

Convalescent plasma therapy was reported in a multi-centre cohort research trial of 45 critically ill patients with COVID-19 admitted to an intensive care unit in Wuhan. The findings showed that convalescent plasma therapy was administered to six patients and no transfusion reactions occurred; however, the study did not provide adequate information about the efficacy of convalescent plasma therapy due to the limited sample size and lack of a randomized control group \[[@bib61],[@bib62]\].

Convalescent plasma therapy could be a promising treatment method for patients with COVID-19. A recent case series from China showed that five critically ill patients with laboratory-confirmed COVID-19 (who had ARDS) improved. After receiving plasma transfusion, their body temperature normalized within 3 days (in four of the five patients), their viral loads became undetectable within 12 days, and three of the five patients were discharged from hospital and were in a stable condition at 37 days post transfusion \[[@bib63]\]. On 24^th^ March 2020, the US FDA approved convalescent plasma therapy for investigational use under the traditional Investigational New Drug Applications regulatory pathway, and for eligible patients who have confirmed COVID-19 and severe or immediately life-threatening conditions such as respiratory failure, septic shock, and/or multiple organ dysfunction or failure \[[@bib64],[@bib65]\]. Notably there are potential risks and ethical issues associated with convalescent plasma therapy, including increased risk of a thrombotic event (from 0.04% to 14.9%), lack of high-quality research in this particular area, and the selection of donors with high neutralizing antibody titres \[[@bib65]\].

In conclusion, this is the first systematic review of medication used to treat patients with COVID-19. Only 41 research articles were eligible for inclusion in this review, mainly conducted in China, of which only three were clinical trials.

The use of corticosteroids to treat patients with COVID-19 was reported most frequently in this review, despite safety alerts issued by WHO and CDC, followed by lopinavir, oseltamivir and arbidol hydrochloride.

Although further research is warranted as the amount of the evidence increases, this review presents the current picture of treatment modalities used for COVID-19. Efficacy and safety profiles of treatments for COVID-19 will need to be characterized in future studies.
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[^1]: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; ICU, intensive care unit; ARDS, acute respiratory distress syndrome; IL-6, interleukin-6; NA, not applicable; IV, intravenous; IM, intramuscular.
